Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity

Free Radical Biology and Medicine

Volumn 43, Issue 12, 2007, Pages 1574-1583

  Zhang, Jinsong ^a   Lu, Hongjuan ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Acute renal failure; Free radicals; Glutathione; Ifosfamide; Thioredoxin reductase

Indexed keywords

AURANOFIN; BUTHIONINE SULFOXIMINE; GLUTATHIONE; IFOSFAMIDE; THIOREDOXIN REDUCTASE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIOXIDANTS; APOPTOSIS; AURANOFIN; BUTHIONINE SULFOXIMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FREE RADICALS; GLUTATHIONE; IFOSFAMIDE; KIDNEY; KIDNEY FAILURE, ACUTE; MALE; MICE; OXIDATION-REDUCTION; THIOREDOXIN-DISULFIDE REDUCTASE;

MUS;

EID: 36249016756     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.08.020     Document Type: Article

References (54)

1. Dechant K.L., Brogden R.N., Pilkington T., and Faulds D. Ifosfamide mesna-a review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42 (1991) 428-467
2. Elias A.D., Eder J.P., Shea T., Begg C.B., Frei E., and Antman K.H. High-dose ifosfamide with mesna uroprotection-a phase-I study. J. Clin. Oncol. 8 (1990) 170-178
3. Rossi R., Godde A., Kleinebrand A., Riepenhausen M., Boos J., Ritter J., and Jurgens H. Unilateral nephrectomy and cisplatin as risk-factors of ifosfamide-induced nephrotoxicity-analysis of 120 patients. J. Clin. Oncol. 12 (1994) 159-165
4. Wagner T. Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet. 26 (1994) 439-456
5. Furlanut M., and Franceschi L. Pharmacology of ifosfamide. Oncology 65 (2003) 2-6
6. Zhang J., Tian Q., Chan S.Y., Li S.C., Zhou S.F., Duan W., and Zhu Y.Z. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab. Rev. 37 (2005) 611-703
7. Kandala J.C., Mrema J.E.K., DeAngelo A., Daniel F.B., and Guntaka R.V. 2-Chloroacetaldehyde and 2-chloroacetal are potent inhibitors of DNA-synthesis in animal-cells. Biochem. Biophys. Res. Commun. 167 (1990) 457-463
8. Sood C., and O'Brien P.J. Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem. Pharmacol. 46 (1993) 1621-1626
9. Lee S.M., Crowther D., Scarffe J.H., Dougal M., Elder R.H., Rafferty J.A., and Margison G.P. Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone-marrow transplantation. Br. J. Cancer 66 (1992) 331-336
10. Nordberg J., and Arnér E.S.J. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 31 (2001) 1287-1312
11. Arnér E.S.J., and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267 (2000) 6102-6109
12. Sandalova T., Zhong L.W., Lindqvist Y., Holmgren A., and Schneider G. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc. Natl. Acad. Sci. USA 98 (2001) 9533-9538
13. Zhong L.W., Arnér E.S.J., and Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc. Natl. Acad. Sci. USA 97 (2000) 5854-5859
14. Gladyshev V.N., Jeang K.T., and Stadtman T.C. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. USA 93 (1996) 6146-6151
15. Tamura T., and Stadtman T.C. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc. Natl. Acad. Sci. USA 93 (1996) 1006-1011
16. Stadtman T.C. Selenocysteine. Annu. Rev. Biochem. 65 (1996) 83-100
17. Fang J.G., and Holmgren A. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo. J. Am. Chem. Soc. 128 (2006) 1879-1885
18. Nordberg J., Zhong L., Holmgren A., and Arnér E.S.J. Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue. J. Biol. Chem. 273 (1998) 10835-10842
19. Srivastava S., Watowich S.J., Petrash J.M., Srivastava S.K., and Bhatnagar A. Structural and kinetic determinants of aldehyde reduction by aldose reductase. Biochemistry 38 (1999) 42-54
20. Biswal S., Maxwell T., Rangasamy T., and Kehrer J.P. Modulation of benzo [α] pyrene-induced p53 DNA activity by acrolein. Carcinogenesis 24 (2003) 1401-1406
21. Kehrer J.P., and Biswal S.S. The molecular effects of acrolein. Toxicol. Sci. 57 (2000) 6-15
22. Park Y.S., Misonou Y., Fujiwara N., Takahashi M., Miyamoto Y., Koh Y.H., Suzuki K., and Taniguchi N. Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 327 (2005) 1058-1065
23. Zhang J.S., Ma K.Y., and Wang H.L. Cyclophosphamide suppresses thioredoxin reductase in bladder tissue and its adaptive response via inductions of thioredoxin reductase and glutathione peroxidase. Chem.-Biol. Interact. 162 (2006) 24-30
24. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82 (1959) 70-77
25. Holmgren A., and Björnstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol. 252 (1995) 199-208
26. Ganther H., and Ip C. Thioredoxin reductase activity in rat liver is not affected by supranutritional levels of monomethylated selenium in vivo and is inhibited only by high levels of selenium in vitro. J. Nutr. 131 (2001) 301-304
27. Rotruck J.T., Pope A.L., Ganther H.E., Swanson A.B., Hafeman D.G., and Hoekstra W.G. Selenium: biochemical role as a component of glutathione peroxidase. Science 179 (1973) 588-590
28. Habig W.H., Pabst M.J., and Jakoby W.B. Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249 (1974) 7130-7139
29. Claiborne A. Catalase activity. In: Greenwald R.A. (Ed). CRC handbook of methods for oxygen radical research (1985), CRC Press, Boca Raton 283-284
30. Sun Y., Oberley L.W., and Li Y. A simple method for clinical assay of superoxide dismutase. Clin. Chem. 34 (1988) 497-500
31. Gromer S., Arscott L.D., Williams C.H., Schirmer R.H., and Becker K. Human placenta thioredoxin reductase-isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 273 (1998) 20096-20101
32. Griffith O.W., and Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butylhomocysteine sulfoximine). J. Biol. Chem. 254 (1979) 7558-7560
33. Baker A., Payne C.M., Briehl M.M., and Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res. 57 (1997) 5162-5167
34. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17 (1998) 2596-2606
35. Freemerman A.J., Gallegos A., and Powis G. Nuclear factor kappa B transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res. 59 (1999) 4090-4094
36. Seo M.S., Kang S.W., Kim K., Baines I.C., Lee T.H., and Rhee S.G. Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J. Biol. Chem. 275 (2000) 20346-20354
37. Hoshi T., and Heinemann S.H. Regulation of cell function by methionine oxidation and reduction. J. Physiol. 531 (2001) 1-11
38. Fang J.G., Lu J., and Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin-a novel molecular mechanism for its anticancer activity. J. Biol. Chem. 280 (2005) 25284-25290
39. Sasada T., Nakamura H., Ueda S., Sato N., Kitaoka Y., Gon Y., Takabayashi A., Spyrou G., Holmgren A., and Yodoi J. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic. Biol. Med. 27 (1999) 504-514
40. Anestål K., and Arnér E.S.J. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J. Biol. Chem. 278 (2003) 15966-15972
41. Cenas N., Prast S., Nivinskas H., Sarlauskas J., and Arnér E.S.J. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J. Biol. Chem. 281 (2005) 5593-5603
42. Arnér E.S.J. Selenium compromised thioredoxin reductase-derived apoptotic proteins (SecTRAPs): potent killers of cancer cells. Free Radic. Res. 40 (2006) S51 [Meeting abstract]
43. Venardos K., Harrison G., Headrick J., and Perkins A. Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart. Clin. Exp. Pharmacol. Physiol. 31 (2004) 289-294
44. Antonovych T.T. Gold nephropathy. Ann. Clin. Lab. Sci. 11 (1981) 386-391
45. Merle L.J., Reidenberg M.M., Camacho M.T., Jones B.R., and Drayer D.E. Renal injury in patients with rheumatoid arthritis treated with gold. Clin. Pharmacol. Ther. 28 (1980) 216-222
46. Hintze K.J., Wald K.A., Zeng H.W., Jeffery E.H., and Finley J.W. Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element. J. Nutr. 133 (2003) 2721-2727
47. Chen Z.H., Saito Y., Yoshida Y., Sekine A., Noguchi N., and Niki E. 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J. Biol. Chem. 280 (2005) 41921-41927
48. Sakurai A., Nishimoto M., Himeno S., Imura N., Tsujimoto M., Kunimoto M., and Hara S. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J. Cell. Physiol. 203 (2005) 529-537
49. Wiencke J.K., and Wiemels J. Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Mutat. Res. 339 (1995) 91-119
50. Gromer S., Schirmer R.H., and Becker K. The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase. FEBS Lett. 412 (1997) 318-320
51. Witte A.B., Anestål K., Jerremalm E., Ehrsson H., and Arnér E.S. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic. Biol. Med. 39 (2005) 696-703
52. Kanzok S.M., Fechner A., Bauer H., Ulschmid J.K., Müller H.M., Botella-Munoz J., Schneuwly S., Schirmer R., and Becker K. Substitution of the thioredoxin system for glutathione reductase in Drosophila melanogaster. Science 291 (2001) 643-646
53. Aleksa K., Ito S., and Koren G. Developmental renal tubular toxicity: a hypothetical framework and experimental approaches. Curr. Ther. Res. 62 (2001) 930-941
54. Zaki E.L., Springate J.E., and Taub M. Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells. Toxicol. in Vitro 17 (2003) 397-402